Castle Biosciences Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio40.91
P/S Ratio2.252.644.5311.7225.89
P/B Ratio1.641.481.552.683.90
Price/Tangible Book2.132.122.273.423.90
Price/FCF20.43317.18
Price/OCF11.51164.43
Enterprise Value Ratios
EV/Revenue1.491.662.697.8623.33
EV/EBITDA20.00
EV/EBIT56.90
EV/FCF13.50285.78
Profitability & Returns
Return on Equity (ROE)0.04%-0.15%-0.17%-0.08%-0.04%
Return on Assets (ROA)0.01%-0.09%-0.13%-0.06%-0.02%
Return on Invested Capital (ROIC)0.04%-0.43%-0.75%-0.77%-0.98%
Return on Capital Employed (ROCE)0.02%-0.17%-0.22%-0.09%-0.02%
Leverage & Solvency Ratios
Debt/Equity0.060.040.030.02
Debt/EBITDA0.96
Debt/FCF0.72
Liquidity Ratios
Current Ratio7.296.208.0914.2120.58
Quick Ratio6.975.907.8113.9420.24
Efficiency Ratios
Asset Turnover0.680.490.300.210.22
Inventory Turnover7.497.5510.677.475.61
Yield & Distribution Ratios
Earnings Yield0.02%-0.10%-0.11%-0.03%-0.01%
FCF Yield0.05%-0.03%-0.08%-0.02%0.00%
Buyback Yield-0.09%-0.03%-0.04%-0.33%-1.19%